193 related articles for article (PubMed ID: 32600534)
21. Is cytoreductive nephrectomy relevant in the immunotherapy era?
Singla N; Ghandour RA; Margulis V
Curr Opin Urol; 2019 Sep; 29(5):526-530. PubMed ID: 31305273
[TBL] [Abstract][Full Text] [Related]
22. Management of non-clear cell renal cell carcinoma: Current approaches.
Tsimafeyeu I
Urol Oncol; 2017 Jan; 35(1):5-13. PubMed ID: 27544302
[TBL] [Abstract][Full Text] [Related]
23. What advances have been made in immune-therapy for renal cell carcinoma?
Verzoni E; Grassi P; Ratta R
Future Oncol; 2017 Apr; 13(8):665-668. PubMed ID: 28183189
[No Abstract] [Full Text] [Related]
24. Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art.
Lebacle C; Pooli A; Bessede T; Irani J; Pantuck AJ; Drakaki A
World J Urol; 2019 Jan; 37(1):115-123. PubMed ID: 29858701
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant therapy in renal cell carcinoma.
Gul A; Rini BI
Cancer; 2019 Sep; 125(17):2935-2944. PubMed ID: 31225907
[TBL] [Abstract][Full Text] [Related]
26. Molecular pathways in renal cell carcinoma: recent advances in genetics and molecular biology.
Su D; Singer EA; Srinivasan R
Curr Opin Oncol; 2015 May; 27(3):217-23. PubMed ID: 25811348
[TBL] [Abstract][Full Text] [Related]
27. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology.
Motzer RJ; Bacik J; Mariani T; Russo P; Mazumdar M; Reuter V
J Clin Oncol; 2002 May; 20(9):2376-81. PubMed ID: 11981011
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant Therapy for Localized High-Risk Renal Cell Carcinoma.
Wood E; Donin N; Shuch B
Urol Clin North Am; 2020 Aug; 47(3):345-358. PubMed ID: 32600536
[TBL] [Abstract][Full Text] [Related]
29. Updates to the Management of Kidney Cancer.
Jonasch E
J Natl Compr Canc Netw; 2018 May; 16(5S):639-641. PubMed ID: 29784745
[TBL] [Abstract][Full Text] [Related]
30. Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma.
Bhindi B; Habermann EB; Mason RJ; Costello BA; Pagliaro LC; Thompson RH; Leibovich BC; Boorjian SA
J Urol; 2018 Sep; 200(3):528-534. PubMed ID: 29574109
[TBL] [Abstract][Full Text] [Related]
31. Up-front Targeted Therapy Prior to Cytoreductive Nephrectomy in Treatment-Naive Patients With Metastatic Renal Cell Carcinoma.
Agarwal N; Shuch B; Pal SK
JAMA Oncol; 2016 Oct; 2(10):1273-1274. PubMed ID: 27254305
[No Abstract] [Full Text] [Related]
32. Patient selection for cytoreductive nephrectomy in combination with targeted therapies or immune checkpoint inhibitors.
Shapiro DD; Abel EJ
Curr Opin Urol; 2019 Sep; 29(5):513-520. PubMed ID: 31305274
[TBL] [Abstract][Full Text] [Related]
33. Editorial comment.
Kübler HR
Urology; 2015 Feb; 85(2):450-1. PubMed ID: 25623718
[No Abstract] [Full Text] [Related]
34. External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
Marconi L; de Bruijn R; van Werkhoven E; Beisland C; Fife K; Heidenreich A; Kapoor A; Karam J; Kauffmann C; Klatte T; Ljungberg B; Matin S; Sjoberg D; Staehler M; Stewart GD; Tanguay S; Uzzo R; Welsh S; Wood L; Wood C; Bex A
World J Urol; 2018 Dec; 36(12):1973-1980. PubMed ID: 30069581
[TBL] [Abstract][Full Text] [Related]
35. Effect of renal embolization in patients with synchronous metastatic renal cell carcinoma: a retrospective comparison of cytoreductive nephrectomy and systemic medical therapy.
Kim SH; Kim JK; Park B; Joo J; Joung JY; Seo HK; Lee KH; Chung J
Oncotarget; 2017 Jul; 8(30):49615-49624. PubMed ID: 28548948
[TBL] [Abstract][Full Text] [Related]
36. Renal Cell Carcinoma of Variant Histology: New Biologic Understanding Leads to Therapeutic Advances.
Salgia NJ; Zengin ZB; Pal SK; Dizman N
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e438642. PubMed ID: 38776514
[TBL] [Abstract][Full Text] [Related]
37. Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agents.
Coinu A; Petrelli F; Barni S
Expert Rev Anticancer Ther; 2016; 16(1):33-43. PubMed ID: 26535485
[TBL] [Abstract][Full Text] [Related]
38. [50 years of renal cell carcinoma].
Doehn C
Aktuelle Urol; 2019 Aug; 50(4):378-385. PubMed ID: 31398756
[TBL] [Abstract][Full Text] [Related]
39. Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USA.
Pal SK; Signorovitch JE; Li N; Zichlin ML; Liu Z; Ghate SR; Perez JR; Vogelzang NJ
Int J Urol; 2017 Apr; 24(4):272-278. PubMed ID: 28253548
[TBL] [Abstract][Full Text] [Related]
40. The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy.
Rini BI; Campbell SC
J Urol; 2007 Jun; 177(6):1978-84. PubMed ID: 17509276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]